Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis

Clinica Chimica Acta

Volumn 462, Issue , 2016, Pages 118-126

  Lee, Jingyun ^a   McKinney, Kimberly Q ^a   Pavlopoulos, Antonis J ^a   Han, May H ^b   Kim, Su Hyun ^c   Kim, Ho Jin ^c   Hwang, Sunil ^a  

^a LEVINE CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Cancer Center   (South Korea)

Author keywords

Cerebrospinal fluid; Exosome; Multiple sclerosis; Neuromyelitis optica; Proteomics

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN B100; CERULOPLASMIN; CHEMOKINE; CHITINASE; COMPLEMENT COMPONENT C4B BINDING PROTEIN; FIBRINOGEN; FIBRONECTIN; GALECTIN 3; GLIAL FIBRILLARY ACIDIC PROTEIN; HAPTOGLOBIN; PROTEOME;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EXOSOME; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; ULTRACENTRIFUGATION; WESTERN BLOTTING; CEREBROSPINAL FLUID; CHEMISTRY; MIDDLE AGED;

ADULT; CEREBROSPINAL FLUID; EXOSOMES; FEMALE; FIBRONECTINS; FLOW CYTOMETRY; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PROTEOME;

EID: 84988009709     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.09.001     Document Type: Article

References (39)

1. [1] Wingerchuk, D.M., Hogancamp, W.F., O'Brien, P.C., Weinshenker, B.G., The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (1999), 1107–1114.
2. [2] Kim, W., Kim, S.H., Kim, H.J., New insights into neuromyelitis optica. J. Clin. Neurol. 7 (2011), 115–127.
3. [3] Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman, A.S., Hinson, S.R., IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005), 473–477.
4. [4] Lennon, V.A., Wingerchuk, D.M., Kryzer, T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004), 2106–2112.
5. [5] Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., Pittock, S.J., Weinshenker, B.G., The spectrum of neuromyelitis optica. Lancet Neurol. 6 (2007), 805–815.
6. [6] Uzawa, A., Mori, M., Kuwabara, S., Neuromyelitis optica: concept, immunology and treatment. J. Clin. Neurosci. 21 (2014), 12–21.
7. [7] Weinshenker, B.G., Wingerchuk, D.M., Vukusic, S., et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 59 (2006), 566–569.
8. [8] Jarius, S., Wildemann, B., Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 23 (2013), 661–683.
9. [9] Uzawa, A., Mori, M., Kuwabara, S., Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol. 24 (2014), 67–73.
10. [10] Okada, K., Matsushita, T., Kira, J., Tsuji, S., B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 74 (2010), 177–178.
11. [11] Uzawa, A., Mori, M., Sawai, S., et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clinica chimica acta. Int. J. Clin. Chem. 421 (2013), 181–183.
12. [12] Wang, H., Wang, K., Wang, C., et al. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 20 (2013), 113–118.
13. [13] Xu, W., Li, R., Dai, Y., et al. IL-22 secreting CD4 + T cells in the patients with neuromyelitis optica and multiple sclerosis. J. Neuroimmunol. 261 (2013), 87–91.
14. [14] Farrokhi, M., Rezaei, A., Amani-Beni, A., Etemadifar, M., Kouchaki, E., Zahedi, A., Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica. Acta Neurol. Belg., 2015.
15. [15] Alvarez, E., Piccio, L., Mikesell, R.J., et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult. Scler. 19 (2013), 1204–1208.
16. [16] Camussi, G., Deregibus, M.C., Bruno, S., Grange, C., Fonsato, V., Tetta, C., Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 1 (2011), 98–110.
17. [17] Gupta, A., Pulliam, L., Exosomes as mediators of neuroinflammation. J. Neuroinflammation, 11, 2014, 68.
18. [18] Saenz-Cuesta, M., Osorio-Querejeta, I., Otaegui, D., Extracellular vesicles in multiple sclerosis: what are they telling us?. Front. Cell. Neurosci., 8, 2014, 100.
19. [19] Pusic, A.D., Pusic, K.M., Kraig, R.P., What are exosomes and how can they be used in multiple sclerosis therapy?. Expert. Rev. Neurother. 14 (2014), 353–355.
20. [20] Minagar, A., Jy, W., Jimenez, J.J., et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 56 (2001), 1319–1324.
21. [21] Jy, W., Minagar, A., Jimenez, J.J., et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Front. Biosci. 9 (2004), 3137–3144.
22. [22] Verderio, C., Muzio, L., Turola, E., et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann. Neurol. 72 (2012), 610–624.
23. [23] Williams, J.L., Gatson, N.N., Smith, K.M., Almad, A., McTigue, D.M., Whitacre, C.C., Serum exosomes in pregnancy-associated immune modulation and neuroprotection during CNS autoimmunity. Clin. Immunol. 149 (2013), 236–243.
24. [24] Sempere, A.P., Berenguer-Ruiz, L., Lezcano-Rodas, M., Mira-Berenguer, F., Waez, M., Lumbar puncture: its indications, contraindications, complications and technique. Rev. Neurol. 45 (2007), 433–436.
25. [25] Wingerchuk, D.M., Lennon, V.A., Pittock, S.J., Lucchinetti, C.F., Weinshenker, B.G., Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (2006), 1485–1489.
26. [26] Polman, C.H., Reingold, S.C., Banwell, B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69 (2011), 292–302.
27. [27] Wingerchuk, D.M., Weinshenker, B.G., The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult. Scler. 18 (2012), 5–10.
28. [28] Hyun, J.W., Kim, S.H., Huh, S.Y., et al. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. Mult. Scler. 21 (2015), 710–717.
29. [29] Watts, J.A., Lee, Y.Y., Gellar, M.A., Fulkerson, M.B., Hwang, S.I., Kline, J.A., Proteomics of microparticles after experimental pulmonary embolism. Thromb. Res. 130 (2012), 122–128.
30. [30] Vizcaino, J.A., Deutsch, E.W., Wang, R., et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32 (2014), 223–226.
31. [31] Abboudi, M., Jeffrey, W.H., Ghiglione, J.F., et al. Effects of photochemical transformations of dissolved organic matter on bacterial metabolism and diversity in three contrasting coastal sites in the Northwestern Mediterranean Sea during summer. Microb. Ecol. 55 (2008), 344–357.
32. [32] Beach, A., Zhang, H.G., Ratajczak, M.Z., Kakar, S.S., Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J. Ovar. Res., 7, 2014, 14.
33. [33] Parthasarathy, V., Martin, F., Higginbottom, A., et al. Distinct roles for tetraspanins CD9, CD63 and CD81 in the formation of multinucleated giant cells. Immunology 127 (2009), 237–248.
34. [34] Scarpini, E., Galimberti, D., Baron, P., et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J. Neurol. Sci. 195 (2002), 41–46.
35. [35] Okamoto, H., Iikuni, N., Kamitsuji, S., Yoshio, T., Minota, S., Kamatani, N., IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology (Oxford) 45 (2006), 232–234.
36. [36] Shimizu, F., Nishihara, H., Sano, Y., et al. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica. PLoS One, 10, 2015, e0122000.
37. [37] Kotha, J., Longhurst, C., Appling, W., Jennings, L.K., Tetraspanin CD9 regulates beta 1 integrin activation and enhances cell motility to fibronectin via a PI-3 kinase-dependent pathway. Exp. Cell Res. 314 (2008), 1811–1822.
38. [38] Ishihama, Y., Oda, Y., Tabata, T., et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol. Cell. Proteomics 4 (2005), 1265–1272.
39. [39] Sempere, L.F., Martinez, P., Cole, C., Baguna, J., Peterson, K.J., Phylogenetic distribution of microRNAs supports the basal position of acoel flatworms and the polyphyly of Platyhelminthes. Evol. Dev. 9 (2007), 409–415.